ArticleMolecular neurodegeneration advances2026
Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs.
Article in Molecular neurodegeneration advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Measurement of different tau species using immunoassays has proven effective for detecting early Alzheimer's disease (AD) pathology. However, assay performance depends on factors such as the tau form targeted (phosphorylated or non-phosphorylated) and the partner antibody used. Here, we evaluated five different antibody combinations for their ability to differentiate amyloid-positive (Aβ +) from amyloid-negative (Aβ -) individuals in cerebrospinal fluid (CSF). Methods: A total of 290 patients were included in the study grouped by amyloid status. We compared four CSF tau assays designed to separate two axes of assay biology, phosphorylation state and fragment targeting (N-terminal vs mid-domain partner antibodies), to determine how these design choices influence capture of AD pathology. Results: All CSF tau biomarkers were markedly elevated in the Aβ + group. Phosphorylated tau assays showed larger fold increases (approximately 3-sixfold) compared with non-phosphorylated assays (~ twofold). In linear regression models, all biomarkers were associated with log-transformed pTau217. ROC analyses demonstrated high accuracy for detection of amyloid positivity across assays (AUC range 0.86-0.95). BD-ptau217 achieved the highest AUC (0.95, 95% CI 0.92-0.97) and fold increase in the Aβ + compared to Aβ - . Conclusions: Our results show that, irrespective of the partner antibody, phosphorylated tau assays are more accurate than assays that also measure non-phosphorylated forms of the protein in differentiating Aβ + from Aβ - individuals. Moreover, among the immunoassays evaluated, BD-pTau217 exhibited a greater fold increase in the Aβ + group than N-terminal pTau217 and Mid-pTau217. Together, these findings underscore the importance of assay configuration for biomarker performance and indicate that BD-pTau217 may offer superior sensitivity for the early identification of AD pathology. Future studies evaluating these assays in plasma are warranted. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s44477-026-00050-z.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.